Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells

By N. Lee, T. Dohjima, G. Bauer, Haitang Li, Ming-jie Li, A. Ehsani, P. Salvaterra, John J. Rossi. Nature Biotechnology, 2002

1,002 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/54ccd87726ba67da456f60fbb7b7abd184f8e779

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. John S. Mattick
2. Weimin He
3. David P. Bartel
4. J. Kurreck
5. L. Aagaard
6. Robert Blelloch
7. John J. Rossi
8. Thomas Tuschl

In Molecular Biology

1. David P. Bartel
2. John S. Mattick
3. John J. Rossi
4. Phillip A. Sharp
5. Thomas Tuschl
6. Marcel E. Dinger
7. Weimin He
8. Tim R. Mercer

Citations in the corpus

• Antisense technologies. Improvement through novel chemical modifications. (2003, methodology): “Alternatively, two short RNA molecules were transcribed separately using two U6 promotors [118,124,125].”
• RNA silencing: Methods and protocols (2006, background): “Two opposing copies of the target sequence are inserted on either side of a “stuffer” DNA, which is required for stability of the plasmid in Escherichia coli, and then the stem loop is cloned into a vector containing an inducible RNA polymerase I promoter (23,24).”
• siRNA-directed inhibition of HIV-1 infection (2002, methodology): “During preparation of this manuscript, a vector-based strategy to silence an HIV-1 gene was reporte”
• Mouse ES cells express endogenous shRNAs, siRNAs, and other Microprocessor-independent, Dicer-dependent small RNAs. (2008, methodology): “1Institute for Regeneration Medicine, Center for Reproductive Sciences, and Department of Urology, University of California at San Francisco, San Francisco, California 94143, USA; 2Whitehead Institute for Biomedical Research, Howard Hughes Medical Institute and Department of Biology, Massachusetts I”
• RNAi therapeutics: principles, prospects and challenges. (2007, methodology): “Synthetic and expressed siRNAs have been used to target a number of early and late HIV-encoded RNAs including the TAR element [91], tat [34]; [92,93], rev [34,92], gag [94,95], env [95], vif [91], nef [91] and reverse transcriptase [93].”
• Non‐coding RNAs: regulators of disease (2010, background): “Hopes for RNA-based and RNA-targeted therapies were bolstered by early successes using siRNAs in human in vitro culture systems [206] and in targeting HIV-1 and human BCL2 with siRNA-like molecules [207–209].”